exponential model for initial response with a linear model for progression. Standard model diagnostics, including visual predictive checks, were applied to ensure model convergence and fit. Results: A total of 56 full-text studies were reviewed, 14 of which were included in the evidence synthesis (16 metformin study-arms, 100 datapoints and 4696 patients). The final model described HbA1c% as a function of time (up to 1.5 years), baseline HbA1c% and T2DM duration. An average amplitude of initial response of 1.54 was estimated, representing the maximal HbA1c% response to therapy. This response increases by 21% and 5% per unit increase in baseline HbA1c% and T2DM duration (years), respectively. The average time to reach 63% of the response amplitude was estimated at 2.30 months, decreasing by 19% for each unit increase in baseline HbA1c% and increasing by 11% for each extra year of T2DM duration. An average coefficient of failure (progression slope) of 0.63/year was estimated, decreasing by 0.21 per unit increase in baseline HbA1c% and increasing by 0.28 per 1-year increase in T2DM duration. Other covariates showed no major effect on model results. ConClusions: The developed model described the time course of HBA1c% well and has potential in the contextualization of information from future/other T2DM studies. PDB4 SyStematic Literature review anD inDirect treatment comPariSon of the efficacy of SemagLutiDe verSuS emPagLifLozin aS aDD-on to BaSaL inSuLin

No abstract

A403embolism (PE) in 2007-2011 were identified for whom out-patient pharmacy dispensing data was available. Cancer, other risk factors and type and duration of anticoagulant treatment (LMWH and/or VKA) within 90 days of diagnosis and recurrence of VTE were assessed. Results: The study cohort included 1,581 VTE patients: 1,053 with DVT and 528 with PE. For 70-86% of the VTE patients, dispensings of anticoagulant treatment were observed within 90 days. The median duration of anticoagulant dispensings among patients for whom both LMWH and VKA dispensings were observed was 3.5 months with provoked VTE and 3.7 months with unprovoked VTE. In these cohorts the observed median dispensing duration of (initial) LMWH treatment was 12 days. Recurrent VTE occurred mostly after discontinuation of anticoagulant treatment. Longer dispensing durations were observed among patients without recurrence. ConClusions: Treatment after VTE as captured in observational healthcare data generally follows the Dutch guidelines. However, many patients received LMWH dispensing covering periods longer than the recommended 5-10 days. Furthermore, among patients with a VTE recurrence shorter duration of anticoagulant treatment was observed compared to patients without a recurrence.

A617more (n= 2), and it caused a reduction in glycosylated hemoglobin (HbA1c) (n= 4). The impact of TTM on medication adherence is still unknown. ConClusions: TTM helps type 2 diabetic patients self-manage their condition, and to reach their goals, hence achieving better clinical outcomes, and quality of life.

No abstract